Comparative preclinical evaluation of AS01 versus other Adjuvant Systems in a candidate herpes zoster glycoprotein E subunit vaccine

References

• O'Connor KM, Paauw DS. Herpes zoster. Med Clin North Am 2013; 97:503-22, ix; PMID:23809711; http://dx.doi.org/10.1016/j.mcna.2013.02.002
   PubMed Web of Science ®Google Scholar
• Gershon AA, Gershon MD, Breuer J, Levin MJ, Oaklander AL, Griffiths PD. Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J Clin Virol 2010; 48 Suppl 1:S2-S7; PMID:20510263; http://dx.doi.org/10.1016/S1386-6532(10)70002-0
   PubMed Web of Science ®Google Scholar
• Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008; 57:1-30; PMID:18528318
   PubMedGoogle Scholar
• Weinberg A, Levin MJ. VZV T cell-mediated immunity. Curr Top Microbiol Immunol 2010; 342:341-57; PMID:20473790
   PubMed Web of Science ®Google Scholar
• Malavige GN, Jones L, Black AP, Ogg GS. Varicella zoster virus glycoprotein E-specific CD4+ T cells show evidence of recent activation and effector differentiation, consistent with frequent exposure to replicative cycle antigens in healthy immune donors. Clin Exp Immunol 2008; 152:522-31; PMID:18363743; http://dx.doi.org/10.1111/j.1365-2249.2008.03633.x
   PubMed Web of Science ®Google Scholar
• Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271-84; PMID:15930418; http://dx.doi.org/10.1056/NEJMoa051016
   PubMed Web of Science ®Google Scholar
• Doan HQ, Ung B, Ramirez-Fort MK, Khan F, Tyring SK. Zostavax : a subcutaneous vaccine for the prevention of herpes zoster. Expert Opin Biol Ther 2013; 13:1467-77; PMID:23984934; http://dx.doi.org/10.1517/14712598.2013.830101
   PubMed Web of Science ®Google Scholar
• Gagliardi AM, Gomes Silva BN, Torloni MR, Soares BG. Vaccines for preventing herpes zoster in older adults. Cochrane Database Syst Rev 2012; 10:CD008858; PMID:23076951
   PubMed Web of Science ®Google Scholar
• Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, Levin MJ, McElhaney JE, Poder A, Puig-Barbera J et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 2015; 372:2087-96; PMID:25916341; http://dx.doi.org/10.1056/NEJMoa1501184
   PubMed Web of Science ®Google Scholar
• Berarducci B, Rajamani J, Zerboni L, Che X, Sommer M, Arvin AM. Functions of the unique N-terminal region of glycoprotein E in the pathogenesis of varicella-zoster virus infection. Proc Natl Acad Sci U S A 2010; 107:282-7; PMID:19966293; http://dx.doi.org/10.1073/pnas.0912373107
   PubMed Web of Science ®Google Scholar
• Berarducci B, Ikoma M, Stamatis S, Sommer M, Grose C, Arvin AM. Essential functions of the unique N-terminal region of the varicella-zoster virus glycoprotein E ectodomain in viral replication and in the pathogenesis of skin infection. J Virol 2006; 80:9481-96; PMID:16973553; http://dx.doi.org/10.1128/JVI.00533-06
   PubMed Web of Science ®Google Scholar
• Fowler WJ, Garcia-Valcarcel M, Hill-Perkins MS, Murphy G, Harper DR, Jeffries DJ, Burns NR, Adams SE, Kingsman AJ, Layton GT. Identification of immunodominant regions and linear B cell epitopes of the gE envelope protein of varicella-zoster virus. Virology 1995; 214:531-40; PMID:8553555; http://dx.doi.org/10.1006/viro.1995.0064
   PubMed Web of Science ®Google Scholar
• Dendouga N, Fochesato M, Lockman L, Mossman S, Giannini SL. Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice. Vaccine 2012; 30:3126-35; PMID:22326899; http://dx.doi.org/10.1016/j.vaccine.2012.01.088
   PubMed Web of Science ®Google Scholar
• Didierlaurent AM, Collignon C, Bourguignon P, Wouters S, Fierens K, Fochesato M, Dendouga N, Langlet C, Malissen B, Lambrecht BN et al. Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells. J Immunol 2014; 193:1920-30; PMID:25024381; http://dx.doi.org/10.4049/jimmunol.1400948
   PubMed Web of Science ®Google Scholar
• Chlibek R, Bayas JM, Collins H, de la Pinta ML, Ledent E, Mols JF, Heineman TC. Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults ≥50 years of age. J Infect Dis 2013; 208:1953-61; PMID:23904292; http://dx.doi.org/10.1093/infdis/jit365
   PubMed Web of Science ®Google Scholar
• Chlibek R, Smetana J, Pauksens K, Rombo L, Van den Hoek JA, Richardus JH, Plassmann G, Schwarz TF, Ledent E, Heineman TC. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine 2014; 32:1745-53; PMID:24508036; http://dx.doi.org/10.1016/j.vaccine.2014.01.019
   PubMed Web of Science ®Google Scholar
• Garçon N, Van Mechelen M. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev Vaccines 2011; 10:471-86; http://dx.doi.org/10.1586/erv.11.29
   PubMed Web of Science ®Google Scholar
• Couch RB, Bayas JM, Caso C, Mbawuike IN, Lopez CN, Claeys C, El IM, Herve C, Laupeze B, Oostvogels L et al. Superior antigen-specific CD4+ T-cell response with AS03-adjuvantation of a trivalent influenza vaccine in a randomised trial of adults aged 65 and older. BMC Infect Dis 2014; 14:425; PMID:25078387; http://dx.doi.org/10.1186/1471-2334-14-425
   PubMed Web of Science ®Google Scholar
• Van Damme P, Leroux-Roels G, Simon P, Foidart JM, Donders G, Hoppenbrouwers K, Levin M, Tibaldi F, Poncelet S, Moris P et al. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials. Vaccine 2014; 32:3694-705; PMID:24674663; http://dx.doi.org/10.1016/j.vaccine.2014.03.040
   PubMed Web of Science ®Google Scholar
• Vossen MT, Gent MR, Weel JF, de Jong MD, van Lier RA, Kuijpers TW. Development of virus-specific CD4+ T cells on reexposure to Varicella-Zoster virus. J Infect Dis 2004; 190:72-82; PMID:15195245; http://dx.doi.org/10.1086/421277
   PubMed Web of Science ®Google Scholar